Avidity Biosciences, Inc. (RNA)
Stock Price:
$29.15 USD
-0.41 (-1.39%)
Updated Sep 25, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.09B |
| Revenue (ttm) |
4.99M |
| Net Income (ttm) |
n/a |
| Shares Out |
37.53M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Sep 25, 2020 |
| Last Price |
$29.15 |
| Previous Close |
$29.56 |
| Change ($) |
-0.41 |
| Change (%) |
-1.39% |
| Day's Open |
29.52 |
| Day's Range |
27.83 - 30.29 |
| Day's Volume |
198,445 |
| 52-Week Range |
23.06 - 37.46 |
More Stats
| Market Cap |
1.09B |
| Enterprise Value |
742.01M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
37.53M |
| Float |
29.25M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
936,760 |
| Short Ratio |
5.94 |
| Short % of Float |
2.61% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
219.04 |
| PB Ratio |
3.36 |
| Revenue |
4.99M |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
351.89M |
| Net Cash / Share |
9.38 |
| Gross Margin |
-244.69% |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$43.33*
(48.64% upside)
Low
34.0
Current: $29.15
High
60.0
Target: 43.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | 2.32 | 0.38 |
| Revenue Growth | 511.87% | - |
| Gross Profit | 2.32 | 0.38 |
| Operating Income | -17.33 | -10.50 |
| Net Income | -24.73 | -11.22 |
| Shares Outstanding | 2.71 | 2.48 |
| Earnings Per Share | -9.12 | -4.53 |
| Operating Cash Flow | 2.49 | -9.66 |
| Capital Expenditures | -0.24 | -0.05 |
| Free Cash Flow | 2.26 | -9.70 |
| Cash & Equivalents | 94.58 | 3.09 |
| Total Debt | 4.94 | 10.32 |
| Net Cash / Debt | 89.64 | -7.23 |
| Assets | 96.91 | 3.98 |
| Liabilities | 27.54 | 45.11 |
| Book Value | -65.36 | -41.13 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Avidity Biosciences, Inc. |
| Country |
United States |
| Employees |
42 |
| CEO |
Sarah Boyce |
Stock Information
| Ticker Symbol |
RNA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: RNA |
| IPO Date |
June 12, 2020 |
Description
Avidity Biosciences, a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of muscle atrophy, duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe diseases. Avidity Biosciences, Inc. was founded in 2012 and is based in La Jolla, California.